Literature DB >> 27604594

Multiple Tumor Excisions in Ipsilateral Kidney Increase Complications After Partial Nephrectomy.

Matthew J Maurice1, Daniel Ramirez1, Ryan J Nelson1, Peter A Caputo1, Önder Kara1,2, Ercan Malkoç1, Jihad H Kaouk1.   

Abstract

INTRODUCTION: The surgical morbidity of ipsilateral synchronous multifocality (ISM) is poorly characterized. We assessed the impact of ISM on complications after robotic partial nephrectomy (RPN). PATIENTS AND METHODS: We abstracted data on RPN cases performed between 2006 and 2015 at our institution. Multifocal disease was characterized by >1 renal mass on preoperative imaging or >1 mass excision during RPN. The primary outcome was the rate of overall postoperative complications. The association between multifocality and complications was evaluated using univariate and multivariable analyses.
RESULTS: Of 1121 cases, 59 (5.3%) had >1 ipsilateral renal mass and 50 (4.5%) required >1 excision. The overall complication rate was 20.3% (230/1121). The radiographic number of ipsilateral renal masses was not significantly associated with complications (20.2% for 1 mass vs. 25.4% for >1 mass, p = 0.338). However, the actual number of ipsilateral mass excisions performed during RPN was significantly associated with complications (20.2% for ≤2 excisions vs. 42.9% for >2 excisions, p = 0.037). Major complications were higher (14.3% vs. 5.3%) for >2 versus ≤2 excision(s), but this difference was not significant (p = 0.174). The most common complications associated with multiple excisions were transfusion, urine leak, arrhythmia, venous thromboembolism, and ileus. On multivariable analysis, number of excisions independently predicted complications (OR 3.1, 95% CI 1.03-9.33, p = 0.041). Other independent predictors of complications included age, race, Charlson score, body mass index, RENAL score, and surgeon experience.
CONCLUSIONS: ISM requiring ≥2 excisions is associated with increased morbidity after RPN. Pending external validation, this information may facilitate clinical decision-making and preoperative patient counseling.

Entities:  

Keywords:  multifocal; partial nephrectomy; postoperative complications; robotic surgical procedures

Mesh:

Year:  2016        PMID: 27604594     DOI: 10.1089/end.2016.0223

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  6 in total

1.  Re: Multiple Tumor Excisions in Ipsilateral Kidney Increase Complications After Partial Nephrectomy (From: Maurice MJ, Ramirez D, Nelson R, et al. J Endourology 2016;30:1200-1206).

Authors:  Adam R Metwalli
Journal:  J Endourol       Date:  2017-07-20       Impact factor: 2.942

2.  A comparison of outcomes for standard and multiplex partial nephrectomy in a solitary kidney: The National Cancer Institute experience.

Authors:  Joseph A Baiocco; Mark W Ball; Asha K Pappajohn; Kareem N Rayn; Gennady Bratslavsky; Shawna L Boyle; William M Linehan; Adam R Metwalli
Journal:  Urol Oncol       Date:  2019-03-20       Impact factor: 3.498

3.  What is the Optimal Management Strategy for Multifocal and Hereditary Kidney Cancer?

Authors:  Joseph A Baiocco; Adam R Metwalli
Journal:  J Ren Med       Date:  2017-04-01

4.  Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes.

Authors:  Matthew J Watson; Abhinav Sidana; Annerleim Walton Diaz; M Minhaj Siddiqui; Ryan A Hankins; Gennady Bratslavsky; W Marston Linehan; Adam R Metwalli
Journal:  J Endourol       Date:  2016-10-20       Impact factor: 2.942

5.  Robot-Assisted Partial Nephrectomy for Patients with Multifocal Renal Tumors Arising in a Solitary Kidney: Report of Three Cases.

Authors:  Hideaki Miyake; Daisuke Motoyama; Yuto Matsushita; Hiromitsu Watanabe; Toshiki Ito; Takayuki Sugiyama; Atsushi Otsuka
Journal:  J Endourol Case Rep       Date:  2020-12-29

Review 6.  Multiplex Partial Nephrectomy, Repeat Partial Nephrectomy, and Salvage Partial Nephrectomy Remain the Primary Treatment in Multifocal and Hereditary Kidney Cancer.

Authors:  Joseph A Baiocco; Adam R Metwalli
Journal:  Front Oncol       Date:  2017-10-20       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.